Medication info
Esomeprazole Magnesium Trihydrate 40 mg (Esomeprazole Magnesium)

Esomeprazole Magnesium Trihydrate 40 mg (Esomeprazole Magnesium)

Prescription medicationTabletOral · Intravenous injection
Ingredient · strength
Esomeprazole Magnesium Trihydrate›44.5mg / 1 tablet
Manufacturer / importer
Hwaile Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
28 tablets (14 tablets/PTP X 2)
Approval status
Active

MFDS item code 201907480 · Approved 2019.10.28 · Insurance code 684501810

Summary

Main use
Treatment of acid-related disorders (including reflux and ulcers), Helicobacter pylori infection, and gastrointestinal problems caused by anti-inflammatory drugs
Who uses it
Adults · Children
Adult dosage
This drug should be swallowed with a liquid such as water and should not be chewed or crushed. Adults Gastroesophageal reflux disease (GERD) Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take it for an additional 4 weeks. Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Once symptoms have resolved, subsequent recurring symptoms may be controlled with 20 mg once daily. Adults may take 20 mg once daily as needed. As-needed use to control recurring symptoms is not recommended for patients at high risk of gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. Combination therapy with antibiotics for eradication of Helicobacter pylori: Administer this drug 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with nonsteroidal anti-inflammatory drug (nonselective or selective COX-2) use: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical studies exceeding 4 weeks have not been conducted. Patients requiring continuous nonsteroidal anti-inflammatory drug use Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. Treatment of Zollinger-Ellison syndrome: The recommended initial dose is 40 mg twice daily. The subsequent dose should be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses exceeding 80 mg per day should be divided into two doses. Maintenance therapy following initiation of prevention of rebleeding due to gastric or duodenal ulcers by intravenous injection: After initiation of prevention of rebleeding due to gastric or duodenal ulcers by intravenous injection, administer 40 mg once daily for 4 weeks. Adults may take 20 mg once daily as needed. As-needed use to control recurring symptoms is not recommended for patients at high risk of gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. Renal impairment: No dose adjustment is necessary. Use with caution because there is limited experience administering this drug to patients with severe renal impairment. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. Patients with severe hepatic impairment should not exceed a dose of 20 mg of this drug. Older adults: No dose adjustment is necessary.
Children's dosage
Adolescents aged 12 years and older — Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take it for an additional 4 weeks. Adolescents aged 12 years and older — Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Adolescents aged 12 years and older — Once symptoms have resolved, subsequent recurring symptoms may be controlled with 20 mg once daily. Children under 12 years of age — There is no experience with administration of this drug to children under 12 years of age.

Ingredients

Manufacturer
Hwaile Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of acid-related disorders (including reflux and ulcers), Helicobacter pylori infection, and gastrointestinal problems caused by anti-inflammatory drugs

  • Gastroesophageal reflux disease
  • erosive esophagitis
  • esophagitis
  • duodenal ulcers
  • peptic ulcers
  • upper gastrointestinal pain
  • upper gastrointestinal discomfort
  • upper gastrointestinal burning sensation
  • gastric ulcers
  • duodenal ulcers
  • Zollinger-Ellison syndrome
  • rebleeding from gastric ulcers
View approved original text

This medication is used for the long-term maintenance therapy of gastroesophageal reflux disease, particularly erosive esophagitis. It is also included in combination therapy with antibiotics for the eradication of Helicobacter pylori, aiding in the treatment and prevention of relapse of duodenal ulcers and peptic ulcers. It is effective for treating upper gastrointestinal symptoms or gastric ulcers caused by nonsteroidal anti-inflammatory drugs and is also used for the prevention of related ulcers. It is applied in the treatment of Zollinger-Ellison syndrome, and is effective for preventing rebleeding and maintenance therapy due to gastric ulcers or duodenal ulcers. Overall, it is widely used for the treatment and prevention of various gastrointestinal diseases.

Dosage and Administration

Adult dosage

This drug should be swallowed with a liquid such as water and should not be chewed or crushed. Adults Gastroesophageal reflux disease (GERD) Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take it for an additional 4 weeks. Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Once symptoms have resolved, subsequent recurring symptoms may be controlled with 20 mg once daily. Adults may take 20 mg once daily as needed. As-needed use to control recurring symptoms is not recommended for patients at high risk of gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. Combination therapy with antibiotics for eradication of Helicobacter pylori: Administer this drug 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with nonsteroidal anti-inflammatory drug (nonselective or selective COX-2) use: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical studies exceeding 4 weeks have not been conducted. Patients requiring continuous nonsteroidal anti-inflammatory drug use Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. Treatment of Zollinger-Ellison syndrome: The recommended initial dose is 40 mg twice daily. The subsequent dose should be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses exceeding 80 mg per day should be divided into two doses. Maintenance therapy following initiation of prevention of rebleeding due to gastric or duodenal ulcers by intravenous injection: After initiation of prevention of rebleeding due to gastric or duodenal ulcers by intravenous injection, administer 40 mg once daily for 4 weeks. Adults may take 20 mg once daily as needed. As-needed use to control recurring symptoms is not recommended for patients at high risk of gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. Renal impairment: No dose adjustment is necessary. Use with caution because there is limited experience administering this drug to patients with severe renal impairment. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. Patients with severe hepatic impairment should not exceed a dose of 20 mg of this drug. Older adults: No dose adjustment is necessary.

Children's dosage

Adolescents aged 12 years and older — Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take it for an additional 4 weeks. Adolescents aged 12 years and older — Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Adolescents aged 12 years and older — Once symptoms have resolved, subsequent recurring symptoms may be controlled with 20 mg once daily. Children under 12 years of age — There is no experience with administration of this drug to children under 12 years of age.

Precautions

This medication should not be administered to certain patients. For example, individuals who are allergic to this drug or any of its components, or those with hypersensitivity to certain antibiotics should not take it. Additionally, individuals with certain heart conditions or nursing mothers should not use this medication. Various side effects may occur, so if unusual symptoms such as headaches, dizziness, dyspepsia, skin rash, or muscle pain occur while taking this drug, consult a doctor immediately. Long-term use requires regular blood tests or magnesium level checks, and caution is needed as the risk of fractures may increase. This drug can interact with other medications; therefore, inform a doctor or pharmacist of any other medications currently being taken. Pregnant or nursing individuals must consult healthcare professionals before use and it is safer to avoid this drug while nursing. In case of overdose, as there is no specific antidote, appropriate treatment should be administered according to symptoms, and it is essential to store this medication out of reach of children.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, mental confusion, depression, aggression, hallucinations, headache, dizziness, paresthesia, drowsiness, dysgeusia, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal distension, nausea, vomiting, xerostomia, stomatitis, gastrointestinal candidiasis, microscopic colitis, increased liver enzymes, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, hair loss, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, drug reactions with eosinophilia and systemic symptoms, fracture, arthralgia, myalgia, muscle weakness, interstitial nephritis, gynecomastia, malaise, increased sweating, Clostridium difficile-associated diarrhea, abdominal distension, allergic reaction, back pain, chest pain, sternal pain, facial edema, facial flushing, fatigue, influenza-like illness, generalized edema, leg edema, lethargy, pain, stiffness, anemia, hypopigmented anemia, cervical lymphadenopathy, epistaxis, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, liver dysfunction, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, dry mouth, vitamin B12 deficiency, weight gain, weight loss, arthritis exacerbation, arthropathy, seizures, fibromyalgia syndrome, hernia, rheumatic polymyalgia, anorexia, apathy, increased appetite, confusion, worsening depression, hypertonicity, sensory loss, erectile dysfunction, insomnia, migraine, worsening migraine, sleep disorder, tremor, visual field loss, dysmenorrhea, menstrual disorder, vaginitis, asthma exacerbation, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, erythematous rash, papular rash, otitis media, altered sense of smell, taste loss, taste distortion, urinary abnormalities, albuminuria, cystitis, dysuria, fungal infection, hematuria, frequency of urination, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyp or nodule, Barrett's esophagus, mucosal discoloration, hernia, systemic lupus erythematosus, cutaneous lupus erythematosus, hypocalcemia, hypokalemia, rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to avoid exposure to air or moisture and should be kept at room temperature, between 1 and 30 degrees Celsius. Proper storage will help maintain the drug's effectiveness over a long period.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

28 tablets (14 tablets/PTP X 2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.